Scarica l'app Stockscreener
2.48
4.62%
-0.12
Scpharmaceuticals Inc Borsa (SCPH) Ultime notizie
JPMorgan Chase & Co. Raises Position in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences - The Manila Times
scPharmaceuticals Expands Investor Outreach: CEO Set for Citizens, Craig-Hallum, and Wainwright Conferences - Stock Titan
Geode Capital Management LLC Boosts Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Stock Market Recap: scPharmaceuticals Inc (SCPH) Concludes at 2.63, a -5.23 Surge/Decline - DWinneX
Purple Biotech (NASDAQ:PPBT) versus scPharmaceuticals (NASDAQ:SCPH) Financial Review - Defense World
Corebridge Financial Inc. Raises Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Raymond James Financial Inc. Makes New $318,000 Investment in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
SCPH stock touches 52-week low at $2.19 amid market challenges - Investing.com
U.S. FDA approves ScPharmaceuticals' heart failure therapy - MarketScreener
Market Cool On scPharmaceuticals Inc.'s (NASDAQ:SCPH) Revenues Pushing Shares 30% Lower - simplywall.st
Charles Schwab Investment Management Inc. Acquires 26,964 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Bank of New York Mellon Corp Raises Stock Position in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
scPharmaceuticals stock hits 52-week low at $2.73 By Investing.com - Investing.com South Africa
scPharmaceuticals stock hits 52-week low at $2.73 - Investing.com India
Maxim Group Cuts scPharmaceuticals (NASDAQ:SCPH) Price Target to $12.00 - Defense World
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2024 Earnings Call Transcript - Insider Monkey
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Report Preview: Wh - GuruFocus
ScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 2025 - MSN
Optimistic Buy Rating for scPharmaceuticals Amid Strong Q4 Results and Promising Developments - TipRanks
scPharmaceuticals Full Year 2024 Earnings: In Line With Expectations - Yahoo Finance
Analyst Expectations For scPharmaceuticals's Future - Benzinga
Maxim Adjusts Price Target on scPharmaceuticals to $12 From $20, Keeps Buy Rating - Marketscreener.com
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: R - GuruFocus
scPharmaceuticals Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call transcript: SC Pharmaceuticals Q4 2024 beats EPS forecast By Investing.com - Investing.com Australia
Earnings call transcript: SC Pharmaceuticals Q4 2024 beats EPS forecast - Investing.com
scPharmaceuticals Inc. SEC 10-K Report - TradingView
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
scPharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
scPharmaceuticals Inc (SCPH) Q4 Earnings: EPS Misses, Revenue Be - GuruFocus
SCPHARMACEUTICALS Earnings Results: $SCPH Reports Quarterly Earnings - Nasdaq
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Earnings Scheduled For March 19, 2025 - Benzinga
SCPHARMACEUTICALS Earnings Preview: Recent $SCPH Insider Trading, Hedge Fund Activity, and More - Nasdaq
ScPharma Eyes New Frontiers For Furoscix - RTTNews
scPharmaceuticals - The Pharma Letter
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 - The Manila Times
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, ... - Post Register
Breakthroughs in Hyperkalemia DrugsMarket Opportunities - openPR
Scpharmaceuticals at Leerink’s Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rhumbline Advisers - Defense World
scPharmaceuticals (SCPH) to Release Earnings on Wednesday - Armenian Reporter
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD - Yahoo
H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target - Investing.com India
Strategic Market Expansion and Strong Sales Foundation Drive Buy Rating for scPharmaceuticals - TipRanks
HC Wainwright Cuts Earnings Estimates for scPharmaceuticals - Defense World
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease - The Manila Times
ScPharmaceuticals Says US FDA Approves Application to Expand Use of Furoscix -March 06, 2025 at 05:42 pm EST - Marketscreener.com
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):